Orion Corp New B Shs (ORINF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Orion's Q1 2026 results webcast and conference call. My name is Tuukka Hirvman and I'm the head of IR here at Orion. In a few moments, we will kick off with a presentation by our CEO, Liisa Hurme, after which you will have the possibility to ask questions either from Liisa or from our CFO, Rene Lindell. We will be first taking the questions through the conference call lines, and after that we will turn on to the webcast chat function. So you may also type in your questions using the chat function of this webcast. And to our Finnish-speaking viewers, this event is held in English, but afterwards, later this afternoon, you will find a Finnish interview of Orion CEO Liisa Hurme on Orion's website. And just before letting Liisa to step in, just a reminder about this disclaimer regarding forward-looking statements. With these words, I'd like to hand over to Liisa. Thank you, Tuukka, and good afternoon on my behalf as well, and welcome to Listen Orion Q1 2026 results. Some highlights from this Q1. All our businesses performed solid, in a solid way, and very well, I would say so. And we also have good news regarding our clinical pipeline. We've been granted, ODM 212 has been granted for fund-raising designation in mesothelioma by FDA, now in April. And we've also started a new Phase 1b-2 study called Eat Coke, which is a basket trial evaluating ODM212 in combination with standard of care treatments in patients with selective advanced solid tumors. And I will talk more about that later on. Also, we have strengthened our executive team. We have appointed Mr. Barclay Vincent as an executive vice president to lead innovative medicines division, and as a member of my executive team as of April 8th. So let's look at the financials. Net sales, a healt...